-+ 0.00%
-+ 0.00%
-+ 0.00%

Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates

MT Newswires·07/16/2026 05:55:26
Listen to the news
05:55 AM EDT, 07/16/2026 (MT Newswires) -- Valerio Therapeutics (ALVIO.PA) and Abivax (ABVX.PA) signed a binding term sheet for an exclusive global research and development collaboration to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases. Under the deal, the French biotechnology company will receive 2.4 million euros upfront and will be eligible for development and commercial milestone payments as well as royalties on net sales and sublicensing revenues, according to a Thursday release. The collaboration, which includes the generation, manufacturing and preclinical evaluation of research candidates, will leverage the expertise of French clinical-stage biotechnology company Abivax and Valerio's targeted technology platforms.